Pravastatin improves outcome in hypercholesterolemia
Pravastatin improves outcome in hypercholesterolemia
Probability (in percent) of a cardiovascular event in patients with a plasma cholesterol concentration between 200 and 300 mg/dL (5.2 to 6.2 mmol/L) and two additional coronary risk factors who were treated with placebo or pravastatin. Pravastatin diminished the incidence of cardiovascular events, a benefit that was demonstrated within six months.
Data from: Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.
